Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients - Wikidata - awgldk - TriplyDB

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients

http://www.wikidata.org/entity/Q24602072

about

Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.Clinical perspectives on human genetic screening to prevent nevirapine toxicity.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Clinical pharmacokinetics of antiretroviral drugs in older persons.Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients.[Tuberculosis and HIV co-infection: clinical trial under the coordination of the Institut Pasteur in Cambodia].Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.Antimicrobial Agents

P2860

Q27687599-C91BF70F-A051-4393-8A80-4A89635349B9 Q28550922-7810154C-BAC7-4483-8A8D-564AF4A42794 Q31074808-695783C0-C1BC-4113-BAF5-F6638845B190 Q34149022-DEDED275-2780-46DF-B729-6AFB94CBBB9F Q34975110-0C17C5EA-5DCE-425F-98F4-C9137C38F38E Q36070182-BA7E9E69-A562-497B-BC1F-C4202D81C5E4 Q36087985-7BC1B884-93A3-47B1-AC13-3035EFE9BE2A Q36276839-BFF02E40-1BF6-4B93-9313-60E61591C0F5 Q36343668-3CC9F69D-7990-4E6A-AC3F-C157C8AFE206 Q36478066-A0665868-6BB5-4E2A-AE80-D817BBC8E9EF Q36630680-5D4E5366-4815-4F6D-B044-225CA24B8086 Q36650954-AB1DE362-3413-4FFB-A6BD-D26D96FDDED4 Q36785839-9453AD4B-E176-430C-913C-46402EB95670 Q36905884-901D8735-9983-4CAA-B476-01B529DE601D Q37037070-474DD38E-0E8F-4A7A-A2AF-F5D4B5965843 Q37509532-6D1F1DB0-DBB6-44D5-B155-42796F9408B8 Q37544678-492A3EF8-9204-4714-8D08-318C5B2A0C7D Q37946959-122E9E21-0FF1-4981-B9F3-7C838D8F5827 Q40736787-82B1A162-457A-4BD2-BEE2-90FD7B3A349B Q43879115-B50A4A17-C0EB-4EF8-8FAA-BE0E7ACB62A9 Q46156964-7946075A-6CF0-4EB6-9D77-224E42FE633D Q46279458-8B8334C4-395C-4F2E-9FF8-93B3E323C056 Q48292658-60D3D05D-08E7-445E-A8DA-C0FA3353748E Q51064185-F8D7E65F-B81F-4006-A457-AC3AAF75C8B6 Q57549163-6D173EAF-E61D-4E74-89E0-AED541F12705

P2860

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients

http://www.wikidata.org/entity/Q24602072

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@ast

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@en

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@nl

type

label

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@ast

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@en

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@nl

prefLabel

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@ast

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@en

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@nl

P1433

Q24602072-CC4F0438-19EC-4BC1-9770-9432429D45DC

P1476

Q24602072-D8449FDA-495C-4EEE-AFD6-EFF0C5598FEE

P2093

Q24602072-022F4373-46B1-493F-9ED4-086D4374065B

Q24602072-031616E6-BAAC-4AF8-84C9-7F8ED301EEBE

Q24602072-5458FAEE-8D41-4FC4-BC8C-DDEF48BC970B

Q24602072-5719ACD2-8B45-4296-88D4-E9BFF4CC2AC1

Q24602072-6461BD6F-CF75-4C26-B953-4CF316C27378

Q24602072-7A1586BB-3333-4527-B673-18EB143CAEB8

Q24602072-B93F16FF-9C42-4AE8-924B-3581708C2838

Q24602072-CDC26549-11CD-47B7-B6D4-B731657A4491

Q24602072-F1DE1B1C-681F-44FE-B760-83E5D071C54B

Q24602072-F5491D99-F62D-41D3-A245-F07F19814825

P2860

Q24602072-00604CB3-689D-419C-A348-C5D09DE5BD3D

Q24602072-0091EB27-F83C-4FCF-BF1A-44EB90C76591

Q24602072-031277F2-002E-4311-99CB-C56DDAEDAF90

Q24602072-0DF29D7E-6E0F-4D33-B5C2-0844D37D8571

Q24602072-131BF71E-70C2-4383-A536-CA3958FBEBEE

Q24602072-18F73D1A-0EF2-44C7-A617-50586088FC43

Q24602072-2DBF888D-6446-4729-BACE-A1221A8131ED

Q24602072-37CF6159-47C0-4006-AC28-DED50412A5D1

Q24602072-3FA14BAD-9E7F-433C-AE9F-76F63F4F49F0

Q24602072-4435FD36-1095-4E51-AC5D-54DBCAE9F49A

P304

Q24602072-28F9A8A3-EBC4-4CBD-8510-7FAAFBDC7C3E

P31

Q24602072-DBD38E94-E4A6-43CE-A372-A33DF953AD8A

P3181

Q24602072-7F0691CB-B7BD-4834-9390-BFE45C07E4AF

P356

Q24602072-288C7ED5-22A8-41BE-85AD-C4AA2A14CFE9

P407

Q24602072-9145A28C-C90A-4283-A64B-1750BB615263

P433

Q24602072-FBCB5980-9359-44BF-9220-99495F001F99

P478

Q24602072-2A504C45-4000-4AC9-ABD2-D282BDC9CC58

P50

Q24602072-1E7AB340-BA7A-47DA-B766-D4A1A2C62616

P577

Q24602072-3BCD1B96-EAE3-4EA2-B7F8-5A8658550305

P5875

Q24602072-5209AEDC-B981-4544-981E-A5BC1C899634

P698

Q24602072-98610818-3CBC-4A2A-BD34-E2AB5A6C4534

P921

Q24602072-2E191C24-3D8C-487A-A33D-FA0657732EDA

Q24602072-3B479F84-AE9A-4369-9D50-EF90C0B57572

Q24602072-AF39AD71-FCF9-4292-9E83-C581B51F0D01

P932

Q24602072-4B4FBFF7-A7A2-47C8-9DEA-EC5FC050AB24

P3181

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetic-pha ...... IV-infected Cambodian patients

@en

P2093

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Clotilde Le Tiec

http://www.w3.org/2001/XMLSchema#string

Céline Verstuyft

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Comets

http://www.w3.org/2001/XMLSchema#string

France Mentre

http://www.w3.org/2001/XMLSchema#string

Laurence Borand

http://www.w3.org/2001/XMLSchema#string

Laurent Becquemont

http://www.w3.org/2001/XMLSchema#string

Monidarin Chou

http://www.w3.org/2001/XMLSchema#string

Olivier Segeral

http://www.w3.org/2001/XMLSchema#string

Vara Ouk

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of East Asia genetic substructure using genome-wide SNP arrays

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates.

Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients

Pharmacogenetics of anti-HIV drugs.

Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.

P304

4432-4439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5109675

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.00512-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45583327

http://www.w3.org/2001/XMLSchema#string

P698

20696882

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

pharmacokinetics

P932

2944557

http://www.w3.org/2001/XMLSchema#string